IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arteiral infusion chemotherapy.
IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arteiral infusion chemotherapy.
复制标题
IL-28B 变异作为接受肝动脉灌注化疗治疗的晚期肝细胞癌患者的预测因子。
DOI：
10.1111/jgh.15035
复制
发表时间：
2020
影响因子：
4.1
通讯作者：
Kaneko S.
中科院分区：
文献类型：
--
作者：
Terashima T;Honda M;Toyama T;Shimakami T;Shimizu R;Takatori H;Arai K;Kawaguchi K;Kitamura K;Yamashita T;Sakai Y;Yamashita T;Mizukoshi E;Kaneko S.
白细胞介素-28 B（IL-28 B）基因的单核苷酸多态性（SNP）与干扰素治疗慢性丙型肝炎感染的有效性相关。IL-28 B基因型是否影响晚期肝细胞癌（HCC）患者的治疗过程和预后尚不清楚。（rs 8099917）使用TaqMan预先设计的SNP基因分型试验评估IL-28 B基因型对接受肝动脉灌注化疗（HAIC）治疗的晚期HCC患者的疗效和预后的影响结果154例接受HAIC治疗的晚期HCC患者中，IL-28 Brs 8099917 TG或GG基因型占17.5%（27/154），IL-28 Brs 8099917 TT基因型占17.5%（27/154）。次要基因型和主要基因型患者的客观缓解率分别为51.9%和29.1%（P= 0.022）。多变量分析显示，次要基因型仍然与HAIC反应相关（比值比，2.620;P= 0.026）。主要基因型和次要基因型患者的中位总生存期分别为14.1和16.9个月，主要基因型患者的总生存期明显短于次要基因型患者（P= 0.027）。多因素分析显示，主要基因型是一个独立的，不利的预后因素（风险比，1.720;P= 0.024）。在选定的人群中获得一致的结果后，倾向评分匹配analysis.ConclusionsTheIL-28 BSNP（rs 8099917）将作为一个有用的预测与HAIC治疗晚期HCC患者的结果。
Background and AimSingle‐nucleotide polymorphisms (SNPs) of the interleukin‐28B (IL‐28B) gene are associated with the effectiveness of interferon therapy for chronic hepatitis C infection. Whether theIL‐28Bgenotype affects the course of treatment and the outcomes of patients with advanced hepatocellular carcinoma (HCC) is unknown.MethodsWe detected theIL‐28BSNP (rs8099917) using TaqMan PreDesigned SNP Genotyping Assays to assess the effects of theIL‐28Bgenotype on treatment efficacy and prognosis of patients with advanced HCC treated with hepatic arterial infusion chemotherapy (HAIC) between September 2003 and January 2015.ResultsThe study included 154 patients who received HAIC to treat advanced HCC, among which 27 (17.5%) had the minor genotype,IL‐28Brs8099917 TG or GG, and the others had the major genotype,IL‐28Brs8099917 TT. The objective response rates of patients with the minor or major genotype were 51.9% and 29.1% (P= 0.022), respectively. Multivariate analysis revealed that the minor genotype remained associated with the response to HAIC (odds ratio, 2.620;P= 0.026). The median overall survival of patients with major or minor genotypes was 14.1 and 16.9 months, respectively, and the overall survival of patients with the major genotype was significantly shorter than that of patients with the minor genotype (P= 0.027). Multivariate analysis revealed that the major genotype was an independent, unfavorable prognostic factor (hazard ratio, 1.720;P= 0.024). Consistent results were obtained in selected populations after propensity score matching analysis.ConclusionsTheIL‐28BSNP (rs8099917) will serve as a useful predictor of the outcomes of patients with advanced HCC treated with HAIC.